Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs

NCT04201197 ↗

Phase 1 Completed 22 enrolled Johns Hopkins University National Center for Complementary and Integrative Health (NCCIH) · collab Washington State University · collab

RandomizedCrossoverDouble-blindBasic science

Summary

This study will evaluate drug-drug interactions between cannabis extracts containing Tetrahydrocannabinol (THC) and THC+ Cannabinoids (CBD) and probe drugs for select CYP450 pathways including: caffeine (CYP1A2), omeprazole (CYP2C19), losartan (CYP2C9), dextromethorphan (CYP2D6), and midazolam (CYP3A).

Timeline

Start: 2020-11-10
Primary completion: 2022-03-16
Completion: 2022-07-28

Publications

Zamarripa CA, Spindle TR, Surujunarain R, Weerts EM, Bansal S, Unadkat JD, Paine MF, Vandrey R. Assessment of Orally Administered Delta9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Delta9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial. JAMA Netw Open. 2023 Feb 1;6(2):e2254752. doi: 10.1001/jamanetworkopen.2022.54752.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Caffeine	Small molecule	100 mg	Oral
Subject	Cannabidiol	Other / unclassified	640 mg	—
Subject	Dextromethorphan	Unknown	30 mg	Oral
Subject	Losartan	Other / unclassified	25 mg	Oral
Subject	Midazolam	Small molecule	1 mg	Oral
Subject	Omeprazole	Other / unclassified	20 mg	Oral
Subject	THC	Unknown	20 mg	Oral

Indications

No indication recorded.